Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 3, 2015, Pages 244-250

  Wagshal, Dana ^a   Sankaranarayanan, Sethu ^b   Guss, Valerie ^b   Hall, Tracey ^b   Berisha, Flora ^c   Lobach, Iryna ^a   Karydas, Anna ^a   Voltarelli, Lisa ^a   Scherling, Carole ^a   Heuer, Hilary ^a   Tartaglia, Maria Carmela ^a,d   Miller, Zachary ^a   Coppola, Giovanni ^e   Ahlijanian, Michael ^b   Soares, Holly ^b   Kramer, Joel H ^a   Rabinovici, Gil D ^a   Rosen, Howard J ^a   Miller, Bruce L ^a   Meredith, Jere ^b   Boxer, Adam L ^a,f   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BOSTON NAMING TASK; CALIFORNIA VERBAL LEARNING TEST 2; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID EXAMINATION; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISODIC MEMORY; FEMALE; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; IMMUNOASSAY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIPLEX POLYMERASE CHAIN REACTION; NEUROPSYCHOLOGICAL TEST; PHONEME; PROGRESSIVE SUPRANUCLEAR PALSY; SEX DIFFERENCE; TAUOPATHY; UNIFIED PARKINSON DISEASE RATING SCALE; WORKING MEMORY; AGED; CEREBROSPINAL FLUID; CLASSIFICATION; GENETICS; MENTAL HEALTH; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; REFERENCE VALUE; SUPRANUCLEAR PALSY, PROGRESSIVE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROGNOSIS; REFERENCE VALUES; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; TAUOPATHIES;

EID: 84923145151     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308004     Document Type: Article

References (40)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
2. Schofield EC, Hodges JR, Bak TH, et al. The relationship between clinical and pathological variables in Richardson's syndrome. J Neurol 2012;259:482-90.
3. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-9.
4. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
5. Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2013;9:189-98.
6. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-52.
7. Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183:95-8.
8. Noguchi M, Yoshita M, Matsumoto Y, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005;237:61-5.
9. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;24:521-36.
10. Rosso SM, van Herpen E, Pijnenburg YA, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 2003;60:1209-13.
11. Yamada K, Cirrito JR, Stewart FR, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 2011;31:13110-17.
12. Karch CM, Jeng AT, Goate AM. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem 2012;287:42751-62.
13. Arai T, Ikeda K, Akiyama H, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004;55:72-9.
14. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8:783-93.
15. Meredith JE Jr, Sankaranarayanan S, Guss V, et al. Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease. PLoS One 2013;8:e76523.
16. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
19. Possin KL, Laluz VR, Alcantar OZ, et al. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia 2011;49:43-8.
20. Wechsler D. Wechsler Adult Intelligence Scale. 3rd edn. San Antonio, TX: The Psychological Corporation, 1997.
21. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test, Second Eed. San Antonio, TX: The Psychological Corporation, 2000.
22. Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003;16:211-18.
23. Delis DC, Kaplan EB, Kramer JH. The Delis-Kaplan executive function system. San Antonio, TX: The Psychological Corporation, 2001.
24. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea & Febiger, 1983.
25. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-14.
26. Fahn S, Elton RL; Committee motUD. Unified Parkinson's Disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health-care Information, 1987:153-63.
27. Coppola G, Chinnathambi S, Lee JJ, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 2012;21:3500-12.
28. Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006;63:1277-80.
29. Maia LF, Kaeser SA, Reichwald J, et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 2013;5:194re192.
30. Hanisch K, Soininen H, Alafuzoff I, et al. Analysis of human tau in cerebrospinal fluid. J Proteome Res 2010;9:1476-82.
31. Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-4.
32. Constantinescu R, Zetterberg H, Holmberg B, et al. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat Disord 2009;15:205-12.
33. Scherling CS, Hall T, Berisha F, et al. CSF neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116-26.
34. Gearing M, Olson DA, Watts RL, et al. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994;44:1015-24.
35. Damoiseaux JS, Seeley WW, Zhou J, et al. Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 2012;32:8254-62.
36. Johansson A, Zetterberg H, Hakansson A, et al. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease. Neurodegener Dis 2005;2:28-35.
37. Liu W, Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology 2004;62:742-8.
38. Luk C, Compta Y, Magdalinou N, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012;123:396-405.
39. Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013;80:402-14.
40. Borroni B, Gardoni F, Parnetti L, et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 2009;30:34-40.